Screen for reactivation of MeCP2 on the inactive X chromosome identifies the BMP/TGF-β superfamily as a regulator of XIST expression

Smitha Sripathy¹, Vid Leko², Robin L. Adriani³, Taylor Loe³, Eric J. Foss³, Emily Dalrymple⁴, Uyen Lao⁴, Tonibelle Gatbonton-Schwager⁴, Kelly T. Carter⁴, Bernhard Payer⁵,⁶,⁷, Patrick J. Padison⁸, William M. Grady⁵,⁶,⁷, Jeannie T. Lee⁹,¹⁰,¹¹, Marisa S. Bartolomei⁹, and Antonio Bedalov⁹,¹²

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; ²Howard Hughes Medical Institute, Massachusetts General Hospital, Boston, MA 02114; ³Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114; ⁴Department of Genetics, Harvard Medical School, Boston, MA 02115; ⁵Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; ⁶Division of Gastroenterology, University of Washington School of Medicine, Seattle, WA 98195; ⁷Epigenetics Program, Department of Cell and Developmental Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104; and ⁸Department of Biochemistry and Medicine, University of Washington School of Medicine, Seattle, WA 98195

Contributed by Jeannie T. Lee, December 31, 2016 (sent for review November 13, 2016; reviewed by Michael R. Green and Ben Philpot)

Rett syndrome (RS) is a debilitating neurological disorder affecting mostly girls with heterozygous mutations in the gene encoding the methyl-CpG–binding protein MeCP2 on the X chromosome. Because restoration of MeCP2 expression in a mouse model reverses neurologic deficits in adult animals, reactivation of the wild-type copy of MeCP2 on the inactive X chromosome (Xi) presents a therapeutic opportunity in RS. To identify genes involved in MeCP2 silencing, we screened a library of 60,000 shRNAs using a cell line with a MeCP2 reporter on the Xi and found 30 genes clustered in seven functional groups. More than half encoded proteins with known enzymatic activity, and six were members of the bone morphogenetic protein (BMP)/TGF-β pathway. shRNAs directed against each of these six genes down-regulated X-inactive specific transcript (XIST), a key player in X-inactivation in differentiated cells. Our results identify pharmacologically suitable targets for reactivation of MeCP2 on the Xi and a genetic circuitry that maintains XIST expression and X-chromosome inactivation in differentiated cells.

X-chromosome inactivation (XCI) is a dosage-compensation phenomenon in which one of the two X chromosomes in female cells becomes transcriptionally silent. This process assures that the ratio of X to autosome expression in females mimics that in males, who have only a single X chromosome. One of the two X chromosomes is inactivated during the random XCI stage after implantation, and that X chromosome remains stably inactivated (1, 2). One of the initiating events in XCI is random expression of XIST (X-inactive specific transcript) from the X chromosome to be inactivated. XIST is a noncoding RNA that coats that chromosome in cis, recruits additional epigenetic modifiers, and renders it transcriptionally inactive. As a result, in any female cell, only one of two alleles on the X chromosome is transcriptionally active.

When an X-linked disease gene is heterozygous, it can be critically important whether the wild-type allele is on the active or inactive X: When the mutant allele is on the active X, transcriptional inactivation of the remaining wild-type allele can cause a complete loss of gene function. However, the resulting disease state could potentially be ameliorated by reactivation of the wild-type allele on the inactive X chromosome (Xi). Several neurodevelopmental disorders in females are caused by heterozygous mutations of X-linked genes including MeCP2 (3), DDX3X (4), KIAA2022 (5), USP9X (6), CDKL5 (7), HDAC8 (8), and SMCA1 (9). Rett syndrome, one of the most common hereditary forms of severe cognitive impairment in girls, is caused by a heterozygous mutation in the MeCP2 gene (3), which encodes a methyl-DNA–binding protein essential for normal development and function of the neurons (10). Because restoration of MeCP2 expression in a mouse model for Rett syndrome reverses neurologic deficits, both in young and adult animals (11), reactivation of the wild-type MeCP2 allele from the inactive X presents a potential therapeutic strategy.

Here we report results of a large-scale genetic screen for regulators of MeCP2 on the Xi. We generated a cell line harboring a MeCP2-linked reporter on the Xi, using a transgenic mouse we described previously (12), and exposed it to a library of 60,000 different small hairpin RNAs (shRNAs). We identified 30 genes whose down-regulation led to reactivation of the silent MeCP2 on the Xi. These genes fell into several functional groups, including mitotic kinases, PI3K/akt signaling, chromatin components, sister chromatid cohesion, acyl-pool biosynthesis, and bone morphogenetic protein (BMP)/TGF-β signaling. Our results identify pharmacologically suitable targets for reactivation of MeCP2 on the Xi and a genetic circuitry that maintains XIST expression and X-chromosome inactivation in differentiated cells.

Significance

Rett syndrome is a neurodevelopmental disorder in girls who are heterozygous for a mutation in the X-linked gene MeCP2. Because cells in these individuals will be missing MeCP2 function only when the wild-type copy of the gene is on the inactive X, reactivation of the silenced copy of MeCP2 presents a potential therapeutic strategy. To identify genes that silence MeCP2 on the inactive X and that could therefore prove valuable as therapeutic targets, we carried out a screen for genes whose down-regulation reactivated a MeCP2 reporter on the inactive X. The 30 genes we have identified reveal a genetic circuitry required for maintenance of X-chromosome inactivation in differentiated cells and a large number of targets suitable for pharmacologic intervention.


Reviewers: M.R.G., University of Massachusetts Medical School; and B.P., University of North Carolina at Chapel Hill.

The authors declare no conflict of interest.

Data deposition: The sequencing data reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE90683).

¹Present address: Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892.
²To whom correspondence may be addressed. Email: lee@molbio.mgh.harvard.edu or abedalov@fhcrc.org.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1621356114/-/DCSupplemental.
protein (BMP)/TGF-β signaling pathway. We found that the BMP signaling pathway is required for maintenance of XIST expression. Furthermore, we show that Rnf12, a known regulator of BMP signaling (13), modulates XIST expression in adult cells, suggesting that the role of Rnf12 as a regulator of XIST during initiation of X-chromosome inactivation in ES cells (14, 15) is retained in differentiated cells through control of BMP signaling.

**Results**

We previously described a transgenic mouse model for monitoring MeCP2 expression with a fusion of the MeCP2 gene with firefly luciferase and hygromycin resistance genes (MeCP2-FL-HR) (12). Whereas the fusion protein proved unstable, resulting in a MeCP2 loss-of-function phenotype in mice, the reporter expression pattern paralleled the expression of the native MeCP2 gene (12). To develop clonal cell lines that have the transgene on either the active (Xa) or inactive X chromosome, we immortalized tail tendon fibroblasts from heterozygous MeCP2-FL-HR/MeCP2 female mice. One cell line with the reporter gene on the Xa (Xa-3) and one with the reporter gene on the Xa (Xa-3) were chosen for further studies. Xa-8 cells had no detectable luciferase activity (Fig. 1A) but expressed the wild-type MeCP2 (Fig. 1B), whereas Xa-3 exhibited the opposite properties. Based on comparison of the luciferase activity in the two cell lines and the known sensitivity of our luciferase assay, we estimated that the expression of the reporter gene on the Xa was ∼100,000-fold lower than the expression on the Xa.

Xa-3 cells, where the wild-type copy of MeCP2 was on the Xi, and subjected it to high-throughput sequencing. The frequency of hairpins in the pre- and postselection specimens was compared with the calculated enrichment for each hairpin (Dataset S1). To reduce the false positive rate, we performed the screen in quadruplicate. The most enriched hairpins in all of the screens were four hairpins targeting XIST, with enrichment varying from 2.4- to 220-fold in different screens (Table S1). Identification of the four hairpins targeting XIST as the most enriched hairpins validated our screening strategy for identifying genes involved in silencing of MeCP2 on the Xi.

We next tested the selected hairpins for down-regulation of their intended target genes and activation of the luciferase reporter. We used several criteria for choosing enriched hairpins for further analysis, including enrichment in at least two of the four screens, the magnitude of the enrichment, and the presence of multiple hairpins targeting the same gene. In instances where a gene was targeted with a single hairpin, we separately tested additional hairpins targeting the same gene. This approach confirmed reactivation of the luciferase reporter for the 30 target genes listed in Table 1. These could be classified in several functional categories, including the TGF-β family, PI3K/AKT signaling pathway, chromatin-modifying enzymes and components, sister chromatid cohesion, mitotic kinases, and acyl donor synthetases (Table 1). The magnitude of activation with individual hairpins ranged from 1.8- to 5.4-fold, with a median of 2.8-fold (Fig. 2A and Dataset S2). The modest level of reactivation with down-regulation of a single target was consistent with results in other screens for X-chromosome reactivation (18–21), indicating that several separate mechanisms are necessary for the tight transcriptional repression of the MeCP2 locus. To determine whether we could increase the level of reactivation by inactivating multiple targets, we combined shRNAs with 5-AZA in a dose that by itself did not cause appreciable reporter reactivation. The level of luciferase activity using this combination was 3.2- to 18.4-fold higher than untreated, with a median of 7.1-fold, which was significantly increased in comparison with activation obtained with hairpins alone (note a different scale in Fig. 2A) and Dataset S2).

To determine whether the same hairpins could reactivate the wild-type MeCP2 allele and not just the reporter, we used Xa-3 cells, where the wild-type copy of MeCP2 was on the Xi, and applied quantitative (q)PCR primers designed to span the MeCP2 stop codon and allow only amplification of wild-type

![Fig. 1.](image-url)

Characterization of the cell lines with the FLHR reporter on the inactive and active X chromosome. (A) Luciferase activity of cells with the reporter on the inactive X (Xi-8) with varying concentrations of 5-AZA, and the reporter on the active X (Xa-3). All measurements were performed in triplicate; error bars indicate SD. LU, light unit; NT, vehicle treated. (B) Western blot showing the presence or absence of the WT copy of MeCP2 in Xa-8 and Xa-3 cells. Brain lysates from 4-wk-old MeCP2/ y and MeCP2-FL-HR/y animals were included as controls. (C) Hygromycin B resistance of cells with the reporter on the active (Xa-3) and inactive (Xi-8) X chromosome. Cells were subjected to hygromycin B at a similar dose and duration (20 μg/mL for 6 d) as was used in the screen, and growth was normalized to untreated controls. Error bars indicate SD; n = 3, P < 0.001. (D) Screen design.

2 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1621356114

Sripathy et al.
Table 1. Validated hits

<table>
<thead>
<tr>
<th>Functional group</th>
<th>Gene</th>
<th>Functional group</th>
<th>Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>TGF-β superfamily</td>
<td>Acvr1</td>
<td>Chromatin components</td>
<td>Dnmt1</td>
</tr>
<tr>
<td></td>
<td>Acvr1b</td>
<td></td>
<td>Hdad3</td>
</tr>
<tr>
<td></td>
<td>Bmpr2</td>
<td></td>
<td>Parp6</td>
</tr>
<tr>
<td></td>
<td>Smad2</td>
<td></td>
<td>Arid4b</td>
</tr>
<tr>
<td></td>
<td>Snip1</td>
<td></td>
<td>Dtx3l</td>
</tr>
<tr>
<td></td>
<td>Zfyve9</td>
<td></td>
<td>Msx2l1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Smarc2d</td>
</tr>
<tr>
<td>Signaling kinases</td>
<td>P3kcb</td>
<td>DNA replication</td>
<td>Titin</td>
</tr>
<tr>
<td></td>
<td>Pdkp1</td>
<td></td>
<td>Gns3</td>
</tr>
<tr>
<td></td>
<td>Sgk2</td>
<td></td>
<td>Mcm8</td>
</tr>
<tr>
<td></td>
<td>Prkd3</td>
<td></td>
<td>Mkn8</td>
</tr>
<tr>
<td></td>
<td>Erb4</td>
<td></td>
<td>Brca2</td>
</tr>
<tr>
<td>Acyl donor synthesis</td>
<td>Acss1</td>
<td>Mitotic kinases</td>
<td>Aukin</td>
</tr>
<tr>
<td></td>
<td>Acaca</td>
<td></td>
<td>Ptk2</td>
</tr>
<tr>
<td>Cohesion</td>
<td>Rad21</td>
<td>Other</td>
<td>XIST</td>
</tr>
<tr>
<td></td>
<td>Nipbl1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Boldfacing indicates genes that have not previously been associated with XCI.

MeCP2 but not the fused gene (Fig. 2C). We confirmed that hairpins for each of the genes combined with a low dose of 5-AZA reactivated the native MeCP2 allele, with the magnitude of reactivation similar to the one in the luciferase assay (Fig. 2C and Dataset S2).

Four of the 30 genes identified in our screen, Acvr1, Aurka, Dnmt1, and Pdkp1, were previously identified in a screen using a CMV-driven GFP reporter on the Xi (22). Moreover, these four genes were targeted with the same hairpins in the two screens, as both screens used the same shRNA library. Given that the methods for detection of reactivation in the two screens were vastly different (hygromycin selection vs. GFP fluorescence), identification of the same hairpins in these two independent screens provides strong cross-validation of these targets and of our screening strategy. However, this finding suggested that inactivation of at least these four genes not only reactivated MeCP2 but also other genes on the Xi. To determine whether the genes in our screen reactivated other genes on the X chromosome, we used a mouse cell line carrying the CMV-luciferase reporter inserted on the Xi (18). We observed that, when combined with low-dose 5-AZA, each of the hairpins that reactivated the MeCP2 reporter also reactivated the CMV-luciferase reporter locus on the Xi (18) (Fig. 2D and Dataset S2), indicating that the hits we have identified are not selective for reactivation of the MeCP2 locus but can instead derepress transcription at other loci on the Xi. We further tested reactivation of a PGK1 gene on the Xi using allele-specific PCR in clonal Mus musculus/Mus spretus hybrid Patski cells (23) focusing on 14 genes that were first linked to XCI in this study. We found that a combination of 5-AZA and shRNA targeting each of these genes led to reactivation of the PGK1 allele on the Xi (Fig. 2E). We conclude that the genes we have identified in our screen repress transcription of other endogenous genes on the Xi.

Given that XIST was a prominent hit in our screen, we next tested whether other genes we identified might repress transcription on the Xi by activating XIST. Such XIST modulators [e.g., protein kinase PDPK1 and activin receptor A, type I (ACVR1)] have recently been found among factors that are required for XCI by Bhattachar et al. (22). When we measured XIST levels in Xi-8 cells expressing shRNAs from our screen (Dataset S2), we found that the knockdown of BMP/TGF-β superfamily members induces a robust and consistent down-regulation of XIST (Fig. 3A). Whereas knockdown of several members of the PI3K/AKT group exhibited modestly reduced XIST levels (Dataset S2), as was previously observed for PDPK1 (22), the magnitude of the effect was smaller relative to the TGF-β pathway. Given the robust effect on XIST levels among all members of the TGF-β superfamily, we focused our attention on this pathway.

The TGF-β superfamily signaling pathway was the largest class of targets after chromatin-modifying enzymes that we identified in our screen. The TGF-β superfamily is composed of cell signaling proteins, including BMPs and TGF-β, which play important roles in development and morphogenesis (24). Upon binding to their respective receptors on the cell surface, members of the TGF-β superfamily activate receptors’ tyrosine kinase activity, leading to phosphorylation and activation of receptor-regulated SMADs (R-SMADs), intracellular signaling proteins that form trimeric complexes and act as transcription factors in the nucleus (24). Our screen identified different components of the TGF-β signaling pathways, including receptors (e.g., Bmpr2) and downstream signaling molecules (e.g., Smad2). We found that down-regulation of each of the targets in the TGF-β superfamily functional group

![Fig. 2. Reactivation of the Xi induced by shRNAs. (A) Firefly luciferase activity induced by shRNAs in Xi-8 cells normalized to shControl. For each graph in A-D a control is plotted followed by an average of three measurements for each shRNA in ascending order, with SD indicated by error bars. P < 0.05 for all hairpins; individual measurements for each shRNA are provided in Dataset S2, rank order of shRNAs is provided on the x axis to facilitate identification of individual hairpins from Dataset S2 in the graphs. (B) Firefly luciferase activity induced by shRNAs in Xi-8 cells in combination with 0.2 μM 5-AZA normalized to the control shRNA in combination with 0.2 μM 5-AZA. At this concentration, the treatment of 5-AZA did not induce a measurable increase in luciferase activity in shControls. (C) Reactivation of the native MeCP2 gene on the inactive X in Xa-3 cells by shRNAs in combination with 0.2 μM 5-AZA. RT-qPCR of MeCP2 mRNA in Xa-3 cells containing different shRNAs in combination with 0.2 μM 5-AZA normalized to shControls in combination with 0.2 μM 5-AZA, measured using the primers indicated by red lines. (D) Reactivation of the CMV-luciferase reporter at the Hprt locus on the inactive X by shRNAs in combination with 0.2 μM 5-AZA. Firefly luciferase activity induced by shRNAs in CMV-FL cells in combination with 0.2 μM 5-AZA normalized to control shRNA in combination with 0.2 μM 5-AZA. (E) Allele-specific RT-PCR for the PGK1 gene on the Xi in M. spretus/M. musculus hybrid Patski cell line demonstrates reactivation using a combination of shRNA and 0.2 μM 5-AZA. The knockout efficiency expressed as the fraction remaining was as follows: Bmpr2, 0.33; XIST, 0.24; Clspn, 0.26; Sgk2, 0.19; Prkd3, 0.28; Erb4, 0.32; Ptk2, 0.23; Parp6, 0.19; Arid4b, 0.50; Dtx3l, 0.37; Msx2l1, 0.25; Smrcd2, 0.24; Ttn, 0.42; and Acss1, 0.27. Expression levels in shRNA-containing cells treated with 0.2 μM 5-AZA are compared with shControl cells treated with 0.2 μM 5-AZA (P < 0.05 for all hairpins), error bars indicate SD.]

Sripathy et al.

PNAS Early Edition | 3 of 6
down-regulates XIST expression (Fig. 3A). For example, inactivation of Acrv1 and Bmp2, which both serve as receptors for the BMP ligand family (25), inhibited XIST expression, suggesting that BMPs up-regulate XIST. To confirm this observation, we treated Xi-8 cells with exogenous BMP2 and examined transcript levels of XIST and several known BMP target genes, including Pai-1, Smad7, and SnoN. Both Smad7 and SnoN are known inhibitors of TGF-β/BMP signaling, and their activation by BMP/TGF-β acts to prevent excessive activation of these pathways. BMP2 caused a time-dependent increase in the mRNA level of all of the aforementioned genes—Pai-1, Smad7, SnoN, and XIST (Fig. 3B). Taken together, these results demonstrate that BMP signaling indeed promotes XIST expression.

Among the key regulators of TGF-β and BMP pathways is Smad7, whose binding to the BMP receptors prevents access of R-SMAD and inhibits their phosphorylation and activation. Smad7 itself is subjected to proteolysis-based regulation by the ubiquitin ligase Rnf12, which acts as an indirect activator of BMP and TGF-β signaling (13, 26). Given the known function of Rnf12 as a regulator of XIST expression during embryonic development (14, 27), we assessed whether Rnf12 might also be involved in maintenance of the Xi in adult cells by regulating BMP/TGF-β signaling. We observed that Rnf12 overexpression in Xi-8 cells increased the expression of Pai-1 (Fig. 3C), a known BMP transcriptional target, similar to the effect of exogenous BMP2 on Xi-8 cells (Fig. 3B). The level of XIST was also increased in cells overexpressing wild-type Rnf12 but not the mutant without catalytic activity (Fig. 3C). Conversely, we found that Rnf12 down-regulation reduced XIST expression and led to activation of the luciferase reporter gene in Xi-8 cells (Fig. 3D). These results suggest that the role of Rnf12 as a regulator of XIST expression during XiCI in ES cells might be retained in adult cells through modulation of BMP signaling and maintenance of XIST expression.

After demonstrating that BMP2 promotes XIST expression, we tested whether a different member of the superfamily, TGF-β, also has a similar role. BMP and TGF-β signaling pathways have been previously shown to act antagonistically in several biological contexts (28) and cell types (29). In contrast, several of the transcriptional targets, particularly those related to negative feedback control such as Smad7 or SnoN, are activated by both TGF-β and BMP signaling. Upon exposure of Xi-8 cells to TGF-β1, we observed a dose-dependent activation of Pai-1, Smad7, and SnoN, similar to cells treated with BMP2. However, in contrast to the up-regulation of XIST observed with BMP2, we found that TGF-β1 down-regulated XIST (Fig. 4A), suggesting that the two pathways are antagonistic with respect to XIST regulation.

Because the effects of the TGF-β superfamily are often cell type- and context-specific, we next tested whether dysregulation of TGF-β signaling might have consequences for XIST expression in vivo. We used previously described animals carrying a liver-specific knockout of TGF-β receptor 2 (Tgbr2LKO) (30). Tgbr2 is an obligatory component of the TGF-β receptor complex essential for signaling by TGF-β but not by BMP ligands (31). We compared the expression of XIST in mice carrying a Tgbr2LKO (30) with the expression level of XIST in their littersmates with the intact Tgbr2. Livers from animals lacking Tgbr2 exhibited 4.2- to 6.3-fold up-regulation of XIST compared with livers from animals with the intact Tgbr2 (Fig. 4B), demonstrating that modulation of TGF-β signaling regulates expression of XIST in vivo. Whereas the majority of genes on the Xi are transcriptionally inactive, a fraction of genes on the Xi are not subjected to XIST-mediated silencing and remain transcriptionally active (23). To determine whether increased expression of XIST induced by Tgbr2 KO might induce their repression, we compared the expression level of two of the “escaper” genes, Kdm5c and Ddx3x, in livers from animals with and without Tgbr2 (Fig. 4B). Because we did not find a significant difference in the Kdm5c or Ddx3x expression level in livers with or without Tgbr2 KO, we conclude that an increased level of XIST induced by Tgbr2 KO does not repress genes that are normally active on the Xi.

Fig. 3. Effect of shRNAs for genes in the BMP/TGF-β group and Rnf12 on XIST levels. (A) shRNAs targeting members of the BMP/TGF-β pathway down-regulate XIST levels. RT-qPCR measurements for XIST normalized to the XIST level in shControl; n = 3; error bars indicate SD. P < 0.05 for each shRNA. (B) BMP2 treatment induces XIST and three known BMP target genes. Cells were treated with BMT2 (50 ng/ml) for the indicated time, and levels of XIST and mRNA for Pai-1, SnoN, and Smad7 were measured using RT-qPCR and normalized to cells treated with vehicle (n = 3; error bars indicate SD; **P < 0.01; ***P < 0.001). (C) Western blot with Rnf12 and Rnf12-GFP in Xi-8 cells. (D) shRNAs targeting Rnf12 (left) decrease XIST levels (n = 3; error bars indicate SD, P < 0.01) and (right) activate the luciferase reporter in Xi8 cells. (n = 3; error bars indicate SD, P < 0.01 for each comparison).
The involvement of Rnf12 in maintenance of XCI via the BMP/TGF-β pathway is particularly intriguing, because Rnf12 has a known role in initiation of XCI that is independent of TGF-β: During ES cell differentiation, Rnf12 induces XIST expression by promoting ubiquitination and degradation of REX1, a pluripotency factor that represses XIST transcription in ES cells (14). Whereas REX1 is no longer expressed in differentiated cells, our results indicate that Rnf12 has retained its role as an XIST activator in differentiated cells through augmentation of BMP signaling. Thus, even though the targets differ in the two contexts, REX1 and Smad7 in ES cells and differentiated cells, respectively, in both situations Rnf12 serves as an X-encoded activator of XIST expression and of XCI by promoting degradation of an autosome-encoded negative regulator of XIST, which might balance autosome-to-X chromosome expression. Together, these results implicate Rnf12 and the BMP signaling pathway in balancing the ratio of autosomes to active the X chromosome in already-differentiated cells.

Even though further work is required to elucidate the exact mechanism by which BMP increases XIST expression, our analysis of published chromatin immunoprecipitation data (33) suggests that the effect of BMP signaling on XIST transcription might be direct, as indicated by the presence of SMAD1, a transcriptional effector of BMP signaling at the XIST-regulatory regions, adjacent to the binding sites of YY1. YY1 serves as an activator of XIST expression during initiation, establishment, and the maintenance phase of XCI (34). Overlapping binding sites for SMAD1 and YY1 have also been identified in the regulatory regions of histone genes, specifically in differentiated cells (33). Furthermore, YY1 and SMAD1 jointly regulate expression of genes during cardiac development (35). Based on these considerations, we suggest that BMP activates XIST expression by promoting YY1-mediated activation of XIST.

Although DNA replication factors and acyl-pool biosynthesis enzymes have not been previously associated with XCI, studies in model organisms implicate both functional groups in faithful propagation of chromatin states. Mutations in DNA replication factors lead to defects in position-effect variegation in flies (36–38) and silencing defects at telomeres and silent mating loci in yeast (39–41). Likewise, perturbations of cellular acyl pools in yeast by genetic inactivation orthologs of Acaca (42) and Accs1 (43) cause global alterations in histone acetylation and genome-wide expression. Identification of DNA replication factors and acyl-pool biosynthesis enzymes in our screen suggests that maintenance of XCI, similar to maintenance of heterochromatin states in other organisms, can be perturbed by defects in DNA replication and changes in availability of acyl donors.

Two major findings of our study raise the prospects of MeCP2 reactivation as a therapeutic strategy. First, approximately two-thirds of the genes (19/30) identified in our screen encode for proteins with known enzymatic activity, highly suitable targets for pharmacologic intervention. Second, we have identified BMP as an inducer of XIST expression, suggesting a pharmacologic strategy for down-regulation of XIST through inhibition of BMP receptor signaling. The BMP receptors, including those identified in our screens, Bmpr2 and Acvr1, have associated tyrosine kinase activity, and small-molecule inhibitors targeting these kinases are available (44, 45). Other kinases have also been identified in the screens: (i) P3-kinase signaling network, including receptor-associated tyrosine kinase Erb4, proximal kinases (e.g., P3K and PDK1), and a distal member (SGK2); (ii) protein kinase C member PRKD3; and (iii) mitotic kinases PLK2 and Aurora. Consistent with the idea that pharmacologic inhibition of kinase signaling networks identified in our screen can reactivate the Xi, work by other groups has demonstrated reactivation of Xi genes by small-molecule inhibitors of PDK1 and P3K (22). Furthermore, Aurora kinase inhibitors have been identified in small-molecule screens for Xi reactivation (22, 46). Given the success of tyrosine kinase

**Fig. 4.** Effect of TGF-β signaling on XIST in XI-B cells and in mice. (A) TGF-β1 down-regulates XIST, whereas inducing three known TGF-β targets in XI-B cells. Cells were treated with TGF-β1 (5 ng/ml) for the indicated times, and levels of XIST and mRNA for PAI-1, Smad7, and Smad5 were measured by RT-qPCR. Error bars indicate SD. All measurements were carried out in quadruplicate. *P < 0.05, **P < 0.01, ***P < 0.001. (B) Albumin-Cre–mediated excision of Tgfb2r in female mouse livers induces XIST and represses Smad7. Mice with liver-specific knockout of Tgfb2r (Tgfb2rLKO) were generated by albumin-Cre–mediated deletion of the floxed Tgfb2r gene (Tgfb2r(co/co)). Cre-Tgfb2r (co/co) littermate controls have an intact Tgfb2r. XIST RNA, Smad7, Kdm5c, and Ddx3x mRNA were measured by RT-qPCR. The levels of XIST, Smad7, Kdm5c, and Ddx3x mRNA in Cre-Tgfb2r (co/co) animals were set to 1. *P < 0.05, **P < 0.01. Error bars indicate SD.

**Discussion**

The observation that restoration of MeCP2 expression reverses neurologic deficits in the mouse model of Rett syndrome (11) creates a compelling case for identifying therapeutic agents that can reactivate wild-type MeCP2 on the inactive X chromosome. To this end, we performed a large shRNA screen and found 30 genes, from seven different functional categories, whose down-regulation reactivated the MeCP2 reporter on the Xi. One of these groups represented members of the BMP/TGF-β signaling pathway, which were not previously linked to XCI. We demonstrate that these genes regulate XIST in tissue culture and that modulation of the TGF-β pathway regulates XIST levels in adult mice, providing a novel mechanism for maintenance of X-chromosome inactivation in differentiated cells.

Four observations served to validate the results of our screen. First, the most prominent hit was XIST, with all four shRNAs in our library appearing among the most enriched shRNAs in all four replicates of our screen. Second, the largest functional group we identified consisted of eight genes involved in chromatin structure and regulation, including Dmnt1 and HADAC3, which had previously been linked to XCI (19, 32). Third, our screen identified 4 of the 13 genes found by Bhatnagar et al. (22) in a screen that used a fundamentally different reporter to identify Xi reactivators, namely GFP driven by the CMV promoter. Finally, our functional screen identified factors involved in sister chromatid cohesion (SCC), whose components were independently identified in a biochemical screen as XIST-interacting factors (20). Taken together, these observations gave us high confidence that the 30 genes identified in our screen are indeed involved in XCI.

The second largest functional group identified in our screen, after genes involved in chromatin regulation, was composed of six genes in the BMP/TGF-β signaling pathway. This result suggested an entirely novel function for this pathway, namely maintenance of the repressed state of the inactive X. Because XIST was the most prominent hit in our screen, we reasoned that if the BMP/TGF-β pathway functioned in the maintenance of XCI, it might do so by regulating levels of XIST. Consistent with this expectation, shRNA-mediated down-regulation of six genes in this group down-regulated XIST. Furthermore, modulating levels of Rnf12, an X-encoded ubiquitin ligase that promotes BMP/TGF-β signaling by degrading Smad7 (13), a repressor of this pathway, had the predicted effects: Overexpression of Rnf12 increased whereas down-regulation of Rnf12 using shRNA decreased levels of XIST.
inhibitors in different pathologic conditions, this class of agents could be used for therapeutic reactivation of genes on the X chromosome.

Our results also highlight potential therapeutic challenges. First, despite identification of the large numbers of genes that are required for maintenance of the silent state of MeCP2 on the X chromosome, this level of reactivation upon inactivation any single target was lost. It is unclear what level of reactivation is required to provide a therapeutic benefit, and it is possible that even low levels would suffice. Furthermore, our observation that combining 5-AZA with inactivation of specific genes led to more potent reactivation than either strategy alone suggests that combination therapies might be effective. Second, even though the use of a reporter gene driven by the native MeCP2 promoter in our screen provided an opportunity to identify targets that reactivate only MeCP2, leaving expression of other genes on the X unaltered, all of the 30 genes identified in the screen reactivated a CMV-driven reporter gene located at a different locus. It is likely that a strategy that effectively reactivates MeCP2 will, at least to some extent, reactivate other loci on the Xi. Even though undesirable side effects resulting from such a nonselective reactivation of the Xi might hinder use of MeCP2 reactivation for therapeutic purposes, a recent study demonstrating grossly normal organogenesis of XIST-deficient female mice suggests that partial deficiency in dosage compensation is surprisingly well tolerated and compatible with both cellular and organismal viability (22, 47).

Materials and Methods

Generation of cell lines, Western blotting, firefly luciferase assays, and allele-specific PCR were carried out using standard techniques. Mice were maintained and cared for using protocols approved by the Fred Hutchinson Cancer Research Center Institutional Animal Care and Use Committee. Complete experimental details and the sequences of the hairpins (Table 52) and the primers used in the study (Table 53) are in SI Materials and Methods.

ACKNOWLEDGMENTS. We thank Kathrin Plath for providing us with CMV-promoter Luci-10 mouse embryonic fibroblasts, Joost Gribnau for the Rnf12 expression plasmids, Ross Dickins for shRNA library, and Christine Disteche for Patski cells. This work was supported by grants from the Rett Syndrome Research Trust (to A.B., M.S.B., and J.T.L.).